Viking Therapeutics announced new clinical data from its VK2735 obesity program at ObesityWeek 2024 on November 4, 2024. The Phase 1 multiple ascending dose study of an oral tablet formulation of VK2735 showed dose-dependent reductions in mean body weight from baseline, ranging up to 8.2% after 28 days of dosing. This translated to up to 6.8% placebo-adjusted mean weight loss, with up to 100% of treated subjects achieving at least 5% weight loss.
The oral VK2735 formulation demonstrated an encouraging safety and tolerability profile, with 99% of treatment-emergent adverse events (TEAEs) reported as mild or moderate. The majority of gastrointestinal adverse events were also mild, suggesting a favorable tolerability profile for a daily oral treatment. Persistent weight loss effects were observed through Day 57, four weeks after the last dose.
Updated results from the Phase 2 VENTURE study of subcutaneous VK2735 also highlighted durable effects. Patients receiving weekly doses achieved statistically significant reductions in mean body weight up to 14.7% from baseline after 13 weeks. Follow-up assessments showed that 94% of the initial weight loss was maintained four weeks after the final dose, supporting the potential for less frequent dosing regimens.
An exploratory analysis from the subcutaneous study indicated that VK2735 treatment increased the odds of prediabetic patients shifting to normoglycemic status. These combined results for both oral and injectable formulations position VK2735 as a strong contender in the rapidly expanding obesity treatment market, demonstrating both potent efficacy and a favorable safety profile.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.